CARBOPLATIN ETOPOSIDE AS 1ST-LINE CHEMOTHERAPY IN ADVANCED OVARIAN-CARCINOMA - A PILOT-STUDY

被引：10

作者：

EIERMANN, W ^{[1
]}

ACHTERRATH, W ^{[1
]}

LENAZ, L ^{[1
]}

HEPP, H ^{[1
]}

机构：

[1] BRISTOL MYERS INT GRP,NEW YORK,NY 10154

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1991年 / 27卷 / 05期

关键词：

D O I：

10.1007/BF00688863

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a pilot study, 18 patients with advanced ovarian cancer were evaluated for tolerance and response to a combination treatment with a fixed dose of carboplatin (350 mg/m2 given i.v. on day 1) and escalated doses of etoposide (70-130 mg/m2 daily given i.v. on days 1-3) as first-line chemotherapy. The maximum tolerated dose of etoposide was 130 mg/m2 when given i.v. on days 1-3 in combination with 350 mg/m2 carboplatin given i.v. every 4 weeks. At these dose levels, bone marrow toxicity was manageable and did not appear to be cumulative. In all, 12 objective responses, including 9 complete responses (CRs) and 3 partial responses (PRs), were achieved in 18 patients; 6 of the 9 CRs were confirmed as pathological CRs by second-look surgery.

引用

页码：389 / 393

页数：5